Bedaquiline resistant Mycobacterium tuberculosis clinical isolates with and without rv0678 mutations have similar growth patterns under varying BDQ drug pressure

Saeed, Dania Khalid; Ashraf, Javaria; Hasan, Zahra; Shakoor, Sadia; Kanji, Akbar; Hasan, Rumina

doi:10.1016/j.tube.2022.102266

Cited by 2 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Insights gleaned from a national survey in Iran would not only inform local TB control strategies but also bolster collaborative efforts aimed at combating drug-resistant tuberculosis in neighboring countries and the broader region. With the emergence of BDQ resistance observed in Pakistan, there is an urgent need for proactive measures to monitor and address drug resistance trends within Iran [ [32] , [33] , [34] ]. Conducting a larger-scale survey encompassing a broader range of MDR-TB isolates from various regions of Iran would furnish a more comprehensive understanding of resistance patterns and trends over time.…”

Section: Discussionmentioning

confidence: 99%

Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in Iran: A cross-sectional analysis

Akbari Aghababa,

Nasiri,

Pakzad

et al. 2024

New Microbes and New Infections

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in Iran: A cross-sectional analysis

Akbari Aghababa,

Nasiri,

Pakzad

et al. 2024

New Microbes and New Infections

View full text Add to dashboard Cite

Study of the Rv1417 and Rv2617c Membrane Proteins and Their Interactions with Nicotine Derivatives as Potential Inhibitors of Erp Virulence-Associated Factor in Mycobacterium tuberculosis: An In Silico Approach

et al. 2023

View full text Add to dashboard Cite

The increasing emergence of Mycobacterium tuberculosis (Mtb) strains resistant to traditional anti-tuberculosis drugs has alarmed health services worldwide. The search for new therapeutic targets and effective drugs that counteract the virulence and multiplication of Mtb represents a challenge for the scientific community. Several studies have considered the erp gene a possible therapeutic target in the last two decades, since its disruption negatively impacts Mtb multiplication. This gene encodes the exported repetitive protein (Erp), which is located in the cell wall of Mtb. In vitro studies have shown that the Erp protein interacts with two putative membrane proteins, Rv1417 and Rv2617c, and the impairment of their interactions can decrease Mtb replication. In this study, we present five nicotine analogs that can inhibit the formation of heterodimers and trimers between these proteins. Through DFT calculations, molecular dynamics, docking, and other advanced in silico techniques, we have analyzed the molecular complexes, and show the effect these compounds have on protein interactions. The results show that four of these analogs can be possible candidates to counteract the pathogenicity of Mtb. This study aims to combine research on the Erp protein as a therapeutic target in the search for new drugs that serve to create new therapies against tuberculosis disease.

show abstract

Bedaquiline resistant Mycobacterium tuberculosis clinical isolates with and without rv0678 mutations have similar growth patterns under varying BDQ drug pressure

Cited by 2 publications

References 46 publications

Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in Iran: A cross-sectional analysis

Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in Iran: A cross-sectional analysis

Study of the Rv1417 and Rv2617c Membrane Proteins and Their Interactions with Nicotine Derivatives as Potential Inhibitors of Erp Virulence-Associated Factor in Mycobacterium tuberculosis: An In Silico Approach

Contact Info

Product

Resources

About